Intravesical cisplatin for superficial bladder tumors

Area of Science:

• Oncology
• Urology
• Pharmacology

Background:

• Superficial bladder cancer presents a challenge for treatment.
• Recurrent and refractory cases require effective therapeutic options.

Purpose of the Study:

• To evaluate the efficacy and toxicity of intravesical cisplatin for superficial bladder cancer.
• To determine the response rate in patients with multiple, recurrent bladder tumors.

Main Methods:

• 24 patients with superficial bladder cancer received weekly intravesical cisplatin (50-150 mg).
• Treatment response was assessed via urinary cytology, cystoscopy, and biopsy.
• Patients had a history of transurethral resections and some prior chemotherapy.

Main Results:

• Only 3 out of 24 patients (13%) achieved complete remission.
• Common toxicities included mild dysuria, pruritus, and rash.
• One patient experienced acute anaphylaxis.

Conclusions:

• Intravesical cisplatin, at the tested dose and schedule, is ineffective for controlling superficial bladder cancer.
• Further research may be needed to explore alternative intravesical therapies.